-
Product Insights
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Drugs In Development, 2023’, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) - Drugs In Development, 2023’, provides an overview of the Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Essential Thrombocythemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Essential Thrombocythemia - Drugs In Development, 2023’, provides an overview of the Essential Thrombocythemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Essential Thrombocythemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Myelofibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myelofibrosis - Drugs In Development, 2023’, provides an overview of the Myelofibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) - Drugs In Development, 2023’, provides an overview of the Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Polycythemia Vera – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycythemia Vera - Drugs In Development, 2023’, provides an overview of the Polycythemia Vera pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
Myelofibrosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031
Myelofibrosis Market Overview The Myelofibrosis market size across the 8MM was valued at $2.39 billion in 2021 and is expected to achieve a CAGR of more than 1% during 2021-2031. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). Incyte was the first company to capitalize on the clinical and commercial potential of the MF market with the landmark approval of its...
-
Product Insights
Post-Polycythemia Vera Myelofibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Post-Polycythemia Vera Myelofibrosis Clinical Trials Market Report Overview The post-polycythemia vera myelofibrosis (PPV-MF) clinical trial market research report provides an overview of PPV-MF clinical trials scenario. The report provides top-line data relating to the clinical trials on PPV-MF. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.